阿立哌唑治疗难治性精神分裂症患者的疗效和安全性

Efficacy and safety of aripiprazole in treatment-resistant schizophrenia

目的:探讨阿立哌唑治疗门诊难治性精神分裂症患者的疗效和安全性。方法:204例入组患者符合中国精神障碍分类与诊断标准第3版精神分裂症的诊断标准,且符合难治性精神分裂症的标准。所有患者接受为期8周的阿立哌唑开放性治疗,在基线、治疗2、4和8周采用阳性与阴性症状量表(PANSS)评定疗效,采用治疗中出现的症状量表(TESS)评定不良反应。结果:阿立哌唑治疗4周开始起效,治疗8周,有效率为55.4%。治疗4和8周,患者PANSS总分减分率有统计学意义(t=2.44,P<0.05;t=3.61,P<0.01),PANSS阳性分减分率有统计学意义(t=3.53,P<0.05;t=3.89,P<0.01),PANSS阴性分减分率有统计学意义(t=3.19,P<0.05;t=4.02,P<0.01)。主要不良反应为焦虑、头晕头痛、失眠、恶心呕吐、嗜睡等。结论:阿立哌唑对于难治性精神分裂症患者的治疗具有一定的疗效,不良反应少,耐受性较好。

Objective： To investigate the clinical efficacy and safety of aripiprazole in treatment-resistant schizophrenia（TRS） in outpatient service. Method：Two hundred and four outpatients who met schizophrenia criteria of Chinese Classification of Mental Disorders-3 and the TRS criteria were treated with single-dosage aripiprazole for 8 weeks. Efficacy and adverse events at baseline ,week 2,4 and 8 after the treatment were assessed by the positive and negative symptom scale （PANSS） and the treatment emergent symptom scale （TESS） , respectively. Results： PANSS total scores significantly decreased （ P 〈 0.05 ） since the end of 4th week treatment,and continued to decrease at the end of 8th week treatment. The responsive rate was 55.4%. The most common adverse events were anxiety, headache, insomnia, nausea, and drowsiness. Conclusion ： These results suggest that aripiprazole is effective and relatively safe in treatment of patients with TRS.